12:00 AM
 | 
Jun 04, 2012
 |  BioCentury  |  Emerging Company Profile

ProteoMediX: Prostate's PI3K biomarkers

ProteoMediX PI3K blood test seeks to avoid unneeded biopsies for prostate cancer

ProteoMedix AG is developing a multiplexed ELISA-based blood test that aims to confirm an initial PSA positive result and reduce unneeded biopsies by monitoring a quartet of biomarkers associated with alterations in PI3K signaling, a common underlying cause of prostate cancer. The company believes its ELISA could have an advantage over competing tests because it measures the activity of a tumor suppressor that has been directly linked to disease development.

While the effectiveness of PSA testing as a screening tool remains a topic of intense debate, there is widespread agreement that new diagnostics are needed to improve the specificity of prostate cancer detection (see BioCentury, Oct. 31, 2011).

Indeed, the U.S. Preventative Services Task Force last month issued its final recommendation against using PSA-based screening in part because of complications from unneeded biopsies performed as a result of false-positive PSA tests.

ProteoMediX spun out from the Swiss Federal Institute of Technology (ETH) Zurich in 2010. ETH researchers had used mass spectrometry to analyze glycosylated proteins in prostate tissue and serum from wild-type mice and mice with prostate-specific deletion of the tumor suppressor PTEN (phosphatase...

Read the full 930 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >